Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
This one-day, in-person study day will explore how systemic anti-cancer treatment (SACT) is being delivered in new ways across cancer services, with a focus on bringing treatment closer to home and improving access for patients. Set within the wider direction of cancer service redesign, the programme looks at how treatment can be provided safely and effectively through community-led pathways, outreach models and home-based care.
Why attend?
This event may be particularly useful for professionals who are involved in redesigning cancer services, developing new treatment pathways, or exploring how SACT can be delivered more flexibly across hospital, community and home settings.
A key strength of the study day is its focus on real-world service models already in use. Rather than discussing transformation in theory, the programme offers practical examples from one of the UK’s most established cancer centres, helping attendees understand what community-focused treatment delivery can look like in practice.
It may also be valuable for teams thinking about how to improve patient experience, reduce hospital attendances and support safe treatment closer to home.
Who is it for?
This event is suitable for a wide range of professionals involved in cancer care and service planning, including:
Oncology professionals.
Clinical and operational leaders.
Cancer service managers.
Commissioners and planners.
Transformation teams.
Community and outreach oncology teams.
Anyone involved in designing or delivering SACT services.
With all experience levels welcome, the study day may appeal to both those already working in service development and those looking to build their understanding of how cancer treatment pathways are changing.